Astrocyte-neuron interplay in Alzheimer's disease: evidence from an innovative and promising pharmacological manipulation in a triple transgenic model of the disease
Background: Alzheimer's disease (AD) is a serious health and economic challenge of the modern age. Current treatments provide only symptomatic relief, making necessary a multitargeted approach against the several pathological processes underlying such disease. In particular, beta-amyloid deposition, tauopathy, astrocyte dysfunction, neuroinflammation and glutamate unbalance recently became promising targets to develop new therapies. In this context, it has been shown that palmitoylethanolamide (PEA) is a multitargeted treatment strategy that provides a novel potential adjunct therapy.